Pharmaron Beijing Co., Ltd — Earnings Release 2020

Mar 29, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [117 x 33] intentionally omitted <==

Pharmaron Beijing Co., Ltd.[*] 康龍化成（北京）新藥技術股份有限公司

(a joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 3759)

INSIDE INFORMATION ANNOUNCEMENT REGARDING THE RESULTS ESTIMATE FOR THE FIRST QUARTER OF 2020

This announcement is made by Pharmaron Beijing Co., Ltd. (the “ Company ” and together with its subsidiaries, the “ Group ”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

I. RESULTS ESTIMATE FOR THE FIRST QUARTER OF 2020

1. Period for the results estimate: January 1, 2020 to March 31, 2020

2. Trend of results estimate:

   • □Loss □Turn loss into profit □✓Up year-on-year □Down year-on-year □Other

3. Results estimate is as follows:

Item	For the three months endedMarch 31, 2020	For the three months endedMarch 31, 2019
Net profitattributable tothe owners ofthe parent	Growth compared withthe same period oflast year: 70% – 100%Profit: RMB92.2116 millionto RMB108.4842 million	Profit: RMB54.2421 million

1

II. PRE-AUDIT STATUS OF THE RESULTS ESTIMATE

The results estimate of the Company for the first quarter of 2020 has not been audited by the auditors of the Company.

III. DISCUSSION OF THE ESTIMATED RESULTS

During the first quarter of 2020, the net profit attributable to the owners of the parent increased by 70% to 100% as compared with the corresponding period of 2019, which is mainly due to the orderly implementation of the business plan of the Company. In the first quarter of 2020, the Company reported stable growth in revenue in its principal business, which improved profitability and resulted in corresponding growth in results.

According to the preliminary estimation by the Company, the net profit attributable to the owners of the parent excluding non-recurring gains or losses for the first quarter of 2020 would be in the range of RMB105.3802 million to RMB121.3468 million.

IV. OTHER RELEVANT INFORMATION

• (1) The results estimate disclosed in this announcement is only a preliminary estimate made by the finance department of the Company and has not been reviewed or audited by the audit committee or the auditors of the Company.

• (2) Details of the Company’s results for the first quarter of 2020 prepared under the PRC Accounting Standards for Business Enterprises will be disclosed in the first quarterly report of 2020 of the Company, which will be published by the Company on the Shenzhen Stock Exchange. Investors are advised to exercise caution when dealing in the shares of the Company.

• (3) The financial information disclosed in this announcement is prepared under the PRC Accounting Standards for Business Enterprises.

By order of the Board Pharmaron Beijing Co., Ltd. 康龍化成（北京）新藥技術股份有限公司 Dr. Lou Boliang* Chairman

Beijing, the People’s Republic of China March 30, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Li Lihua, Ms. Chen Guoqin, Ms. Shen Rong and Mr. Tsang Kwan Hung Benson as independent non-executive Directors.

• For identification purposes only

2